Literature DB >> 29271540

Characterization of CD127-  CD25++ Treg from human colostrum.

Arturo Cérbulo-Vázquez1, Graciela Hernández-Peláez2, Lourdes A Arriaga-Pizano3, Paulina Bautista-Pérez4,5, Jannett Romero-Venado4,6, Julio C Flores-González4,7, Ricardo Figueroa-Damian4, Diana Soriano-Becerril4, Ismael Mancilla-Herrera4.   

Abstract

PROBLEM: Breastfeeding's influence on the tolerance to environmental antigens is essential for short- and long-term homeostasis for children. Colostrum is rich in leucocytes, but it is unknown whether regulatory T cells (Treg) account for part of this cell population. METHOD OF STUDY: Frequencies of CD127-  CD25++ Treg and levels of immunoregulatory-associated cell markers were determined in colostrum and were compared with autologous blood cells. In addition, we evaluated whether the birth conditions can affect these features.
RESULTS: Higher frequencies of CD127 - CD25++ Treg cells expressing Foxp3 and CD45RO were observed in the colostrum. The cells' CD25, CD152, CD279, and TGF-β expression levels were greater than those in autologous blood cells. In addition, the CD279 and TGF-β expressions of colostrum CD127-  CD25++ Treg cells were influenced by gestational age and delivery mode.
CONCLUSION: The higher proportion of these cells with a function-associated phenotype may reflect certain tolerogenic effects of breastmilk on newborns and infants, contributing to immune system homeostasis.
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Treg cells; colostrum; delivery mode; gestational age; immune tolerance

Mesh:

Substances:

Year:  2017        PMID: 29271540     DOI: 10.1111/aji.12806

Source DB:  PubMed          Journal:  Am J Reprod Immunol        ISSN: 1046-7408            Impact factor:   3.886


  1 in total

Review 1.  Human Breast Milk: From Food to Active Immune Response With Disease Protection in Infants and Mothers.

Authors:  Gatien A G Lokossou; Léonce Kouakanou; Anne Schumacher; Ana C Zenclussen
Journal:  Front Immunol       Date:  2022-04-05       Impact factor: 8.786

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.